Enfusion, Inc. (NYSE:ENFN) Given Consensus Recommendation of “Reduce” by Brokerages

Enfusion, Inc. (NYSE:ENFN) has been given an average rating of “Reduce” by the six ratings firms that are covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $9.33.

A number of research analysts have recently weighed in on the stock. Piper Sandler raised their price target on shares of Enfusion from $9.00 to $10.00 and gave the company a “neutral” rating in a report on Wednesday, December 20th. JPMorgan Chase & Co. downgraded shares of Enfusion from a “neutral” rating to an “underweight” rating and cut their price target for the company from $11.00 to $9.00 in a report on Tuesday, January 30th. The Goldman Sachs Group lowered shares of Enfusion from a “neutral” rating to a “sell” rating and lowered their target price for the company from $9.00 to $8.00 in a research note on Wednesday, February 28th. Finally, Bank of America raised their target price on shares of Enfusion from $8.00 to $9.00 and gave the company an “underperform” rating in a research note on Wednesday, March 13th.

Institutional Trading of Enfusion

Several hedge funds and other institutional investors have recently bought and sold shares of ENFN. Lazard Asset Management LLC acquired a new position in Enfusion in the fourth quarter worth about $28,000. Amalgamated Bank lifted its position in shares of Enfusion by 33.7% during the 3rd quarter. Amalgamated Bank now owns 5,230 shares of the company’s stock worth $47,000 after buying an additional 1,317 shares during the period. UBS Group AG boosted its stake in Enfusion by 1,189.8% in the 4th quarter. UBS Group AG now owns 6,204 shares of the company’s stock valued at $60,000 after buying an additional 5,723 shares in the last quarter. Citigroup Inc. grew its position in Enfusion by 24.2% in the first quarter. Citigroup Inc. now owns 7,139 shares of the company’s stock valued at $91,000 after acquiring an additional 1,390 shares during the period. Finally, Barclays PLC raised its stake in Enfusion by 494.6% during the fourth quarter. Barclays PLC now owns 7,248 shares of the company’s stock worth $70,000 after acquiring an additional 6,029 shares in the last quarter. 81.05% of the stock is currently owned by institutional investors and hedge funds.

Enfusion Stock Up 1.1 %

ENFN stock opened at $9.27 on Friday. The company has a market cap of $1.19 billion, a price-to-earnings ratio of 115.83, a PEG ratio of 2.79 and a beta of 1.00. The company has a 50 day moving average of $9.01 and a two-hundred day moving average of $9.11. Enfusion has a 12-month low of $7.37 and a 12-month high of $11.56.

Enfusion (NYSE:ENFN) last released its quarterly earnings results on Tuesday, March 12th. The company reported $0.01 earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). The business had revenue of $46.49 million for the quarter, compared to the consensus estimate of $45.56 million. Enfusion had a net margin of 3.45% and a return on equity of 10.30%. On average, research analysts anticipate that Enfusion will post 0.07 EPS for the current year.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.